Clinical trials: Androgen Deprivation Therapy
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
This randomized phase II trial studies how well abiraterone acetate and antiandrogen therapy, with or without cabazitaxel and prednisone, work in treating patients with castration-resistant prostate cancer previously treated with…
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone
- Trial name
- NCT03419234
- Testing
- Abiraterone Acetate, Androgen deprivation therapy, Cabazitaxel
- Where
- 672 sites in United States, Puerto Rico
- Volunteers
- 223 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Prostate Cancer, Biochemical Recurrence
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
To evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy(ADT) and standard salvage radiation therapy(SRT) or SRT combination with ADT in prostate cancer patients with biochemical…
- Trial name
- NCT06305832
- Testing
- Rezvilutamide, Androgen deprivation therapy (ADT), SRT
- Where
- 2 sites in China
- Volunteers
- 102 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Prostate Cancer
Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients
This is an open-label, multi-centre single arm trial to investigate long-term safety and tolerability of degarelix in Korean patients with prostate cancer.
- Trial name
- NCT01215513
- Testing
- Degarelix
- Where
- 11 sites in South Korea
- Volunteers
- 127 people
- Sponsor
- Ferring Pharmaceuticals
Adenocarcinoma of the Prostate
Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate
To evaluate the efficacy of LHRH agonist with adjuvant pelvic radiation therapy in post radical prostatectomy patients with high risk pathological features for failure.
- Trial name
- NCT01255891
- Testing
- Androgen suppression plus radiation therapy
- Where
- 2 sites in Canada
- Volunteers
- 46 people
- Sponsor
- Dr. Tamim Niazi
Prostate Cancer, Prostatic Neoplasms
PROWESS (PROstate Cancer Wearables Exercise and Structured Supports): A Pilot Supportive Care Intervention
The goal of this research study is to conduct an open pilot of a behavioral change intervention called PROstate Cancer Wearables, Exercise, and Structured Supports (PROWESS) for integrating health behavior change tools and to…
- Trial name
- NCT05755490
- Testing
- PROWESS
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Massachusetts General Hospital
Prostate Cancer
A Trial of Degarelix in Patients With Prostate Cancer
A phase 3, open-label, parallel group, one year trial comparing the efficacy and safety of degarelix 3-month depot with the established therapy goserelin acetate 3-month implant in patients with prostate cancer.
- Trial name
- NCT00946920
- Testing
- Degarelix, Goserelin acetate
- Where
- 126 sites in United States, Belgium and 12 more
- Volunteers
- 859 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)
The goal of this clinical research is to learn if treatment with androgen deprivation therapy in combination with surgery or radiation therapy can prolong the progression-free survival of oligometastatic prostate cancer than…
- Trial name
- NCT02742675
- Testing
- Bicalutamide, goserelin acetate, flutamide
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
High Risk Prostate Cancer
Surgical Treatment With or Without Apalutamide in Subjects With High Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy and Staged as Oligometastatic With PSMA-PET
This is a phase 2, open-label, randomized study of adjuvant treatment in subjects with high-risk prostate cancer who are candidates for RP with PLND based on M0 status at conventional imaging, but staged as oligometastatic with…
- Trial name
- STAPLE (NCT06758882)
- Testing
- Apalutamide, Androgen receptor (AR) inhibitor
- Where
- Italy
- Volunteers
- 94 people
- Sponsor
- Marco Oderda
Prostate Cancer
Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer
This study aims to determine whether early treatment with zoledronic acid, that is given during the early phase of advanced prostate cancer, will be more efficacious than delayed treatment
- Trial name
- NCT00242567
- Testing
- Zoledronic Acid, Androgen Deprivation Therapy (ADT)
- Where
- 27 sites in Australia, Brazil and 8 more
- Volunteers
- 522 people
- Sponsor
- Novartis Pharmaceuticals
PSA Level Greater Than Two, Stage IV Prostate Adenocarcinoma AJCC v7
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
This phase II trial studies how well hormone therapy and intensity-modulated radiation therapy work in treating patients with prostate cancer that has spread to other places in the body.
- Trial name
- NCT00544830
- Testing
- Bicalutamide, Goserelin Acetate, Intensity-Modulated Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer
Investigating Bone and Skeletal Muscle Interaction in Men With Prostate Cancer
The overall goal of this pilot project is to test the hypothesis that a decline in muscle strength precedes the decline in bone strength in men undergoing androgen deprivation therapy (ADT) for prostate cancer.
- Trial name
- NCT03386812
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Texas Southwestern Medical Center
High-risk Prostate Cancer
Conventional Versus Hypofractionated Radiation in High Risk Prostate Patients
Hypofractionated regimen in high-risk prostate cancer will allow the investigators to deliver higher biological doses to targets in order to improve tumor control and with acceptable rectal toxicity compared to conventional…
- Trial name
- CHIRP (NCT01488968)
- Testing
- Standard Radiation Treatment, Hypofractionated radiation treatment
- Where
- Canada
- Volunteers
- 111 people
- Sponsor
- AHS Cancer Control Alberta
Prostate Cancer, Mild Cognitive Impairment
PET Imaging in MCI Following ADT for PCa
Mild cognitive impairment (MCI) with ageing is thought in part to be related to reduced serum sex hormones which is well-recognized, especially in females, but poorly understood.
- Trial name
- NCT02061345
- Where
- United Kingdom
- Volunteers
- 11 people
- Sponsor
- Imperial College London
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
This phase I trial tests the change in androgen receptor sensitivity, side effects and effectiveness of bipolar androgen therapy, using testosterone, in patients with castration resistant prostate cancer that has spread to other…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT06305598
- Testing
- Biopsy, Bone Scan, Computed Tomography
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Roswell Park Cancer Institute
Bone Loss, Prostate Cancer
Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer
The primary objective of this study is to determine whether zoledronic acid (Zometa) given once annually increases bone mineral density in men receiving hormone therapy for prostate cancer.
- Trial name
- NCT00181584
- Testing
- Zoledronic acid
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
High-risk Localized Prostate Cancer
A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.
Researchers are looking for a better way to treat men who have high-risk localized prostate cancer, which refers to a type of prostate cancer that is still confined to the prostate gland but has certain characteristics that make…
- Trial name
- CHINANEO (NCT07450599)
- Testing
- Darolutamide, ADT
- Where
- 23 sites in China
- Volunteers
- 250 people
- Sponsor
- Bayer
Prostate Cancer, Castrate Sensitive Prostate Cancer
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
The purpose of this study is to assess the safety and effectiveness of radiation therapy with hormone therapy (ADT) and chemotherapy as an investigational study treatment for prostate cancer.
- Conditions
- Prostate Cancer, Castrate Sensitive Prostate Cancer, Oligometastatic Disease
- Trial name
- NCT04748042
- Testing
- Abiraterone, Prednisone, External Beam Radiotherapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Michigan Rogel Cancer Center
Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer
Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
Evaluate whether the combination of Rezvilutamide and androgen deprivation therapy (ADT) with docetaxel improves overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) compared to the…
- Conditions
- Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Chemotherapy Effect
- Trial name
- NCT05983783
- Testing
- Docetaxel, Rezvilutamide
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Osteoporosis, Prostate Cancer
Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
RATIONALE: Zoledronate may prevent bone loss associated with long term androgen deprivation therapy. It is not yet known whether zoledronate combined with calcium is more effective than calcium alone in preventing bone loss.
- Trial name
- NCT00058188
- Testing
- cholecalciferol, calcium gluconate, zoledronic acid
- Where
- 3 sites in United States
- Volunteers
- 53 people
- Sponsor
- Northwestern University
Prostate Cancer
Elimination of Prostate Cancer Treatment Side Effects Using a Nutraceutical
Does nutraceutical N-111 lower the number of side effects occurring during ADT + External Beam Radiation (EBR) prostate cancer treatment?
- Trial name
- NCT06643494
- Testing
- N-111
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Optimal Health Research